Trial Profile
A phase IIa trial of durvalumab in combination with tumor-infiltrating lymphocytes in patients with metastatic melanoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 23 Dec 2015 New trial record